FindTrial
Sign In

Real-World Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Multicenter Retrospective Analysis

Real-World Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Multicenter Retrospective Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112170
Enrollment
Unknown
Registered
2025-11-11
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Short-cycle group:None
Standard-cycle group:None

Sponsors

Second Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18–80 years. 2. Pathological confirmation: Stage IIA–IIIB NSCLC (AJCC 8th edition). 3. Treatment record: Received neoadjuvant immunotherapy (PD-1/PD-L1 inhibitors) combined with chemotherapy. 4. Surgical completion: Underwent R0 resection with evaluable postoperative pathological specimens. 5. Complete follow-up: >=6 months of imaging or survival data available

Exclusion criteria

Exclusion criteria: 1. Driver gene positivity (EGFR/ALK/ROS1 mutations). 2. Prior neoadjuvant radiotherapy or targeted therapy causing confounding effects; 3. Clinical data is missing.

Design outcomes

Primary

MeasureTime frame
MPR,Major Pathological Response;—

Secondary

MeasureTime frame
Pathologic Complete Response;—

Countries

china

Contacts

Public ContactChen Liang

Second Affiliated Hospital of Army Medical University, PLA

wanganhui1995@163.com+86 23 6877 4616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026